Digital Humans in Extremes: Insights from Frontiers Health 2025 pharmaphorum chatted with Jack Kreindler (WellFounded) after his onstage session at Frontiers Health 2025.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.